SCHEMBL293192

SCHEMBL293192

O=C(CCl)OCCc1ccccc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.53
PPARG P37231 5/20 0.46
PPARA Q07869 5/20 0.46
TP53 P04637 1/20 0.44
HTT P42858 1/20 0.44
CYP4F2 P78329 2/20 0.43
CYP4A11 Q02928 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 3/20 0.41
TSHR P16473 1/20 0.41
SLC16A3 O15427 2/20 0.41
ALOX15 P16050 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30379181 1.00 FOLH1 (0.53) FOLH1PPARGPPARATP53HTT
SCHEMBL2543662 0.91 FOLH1 (0.50) FOLH1TP53HTTCYP4F2CYP4A11
SCHEMBL30873521 0.83 TP53 (0.54) FOLH1PPARGPPARATP53HTT
SCHEMBL292345 0.83 TP53 (0.54) FOLH1PPARGPPARATP53HTT
SCHEMBL2425935 0.78 TDP1 (0.63) TP53TDP1ALDH1A1TSHRMEN1
SCHEMBL7071110 0.77 FOLH1 (0.66) FOLH1TP53HTTALDH1A1TSHR
SCHEMBL70392 0.76 FOLH1 (0.76) FOLH1TP53HTTALDH1A1TSHR
SCHEMBL30365583 0.76 FOLH1 (0.76) FOLH1TP53HTTALDH1A1TSHR
SCHEMBL1268521 0.76 TDP1 (0.38) PPARGPPARATP53CYP4F2CYP4A11
SCHEMBL1268522 0.76 ALDH1A1 (0.40) HTTCYP4F2CYP4A11TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
EP-4419513-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2025-08-27 EP disclosed
US-12384800-B2 Antitumoral compounds PHARMA MAR, S.A. (ES) 2025-08-12 US disclosed
US-20250243174-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2025-07-31 US disclosed
WO-2025050647-A1 IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF 晟迪生物医药(苏州)有限公司 2025-03-13 WO disclosed
US-12215100-B2 Anticancer compounds PHARMA MAR, S.A. (ES) 2025-02-04 US disclosed
US-20240279248-A1 SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF MELINTA SUBSIDIARY CORP. 2024-08-22 US disclosed
US-12006311-B2 Compounds for use in preventing or treating cancer FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) 2024-06-11 US disclosed
CN-114751920-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
CN-114736219-B Antitumor compounds 法马马有限公司 2024-06-07 CN disclosed
EP-1485707-A4 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS INC (US) 2005-11-16 EP disclosed
EP-1583972-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK Pharmaceuticals, Inc. (US) 2005-10-12 EP disclosed
US-20050042771-A1 Identifying non-drug targets; use in drug design for improving knowledge of drug-target and drug-non-target interactions, so that drug adverse reactions can be reduced or eliminated in drugs such as troglitazone, rosiglitazone, pioglitazone, methotrexate, atorvastatin, celecoxib, rofecoxib, cerivastatin CAPROTEC BIOANALYTICS GMBH (DE) 2005-02-24 US disclosed
EP-1485707-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK Pharmaceuticals, Inc. (US) 2004-12-15 EP disclosed
WO-2004064972-A9 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS INC (US) 2004-09-16 WO disclosed
WO-2004064972-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS, INC. (US) 2004-08-05 WO disclosed
WO-2003092581-A9 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS INC (US) 2004-02-19 WO disclosed
WO-2003092581-A2 CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS HK PHARMACEUTICALS, INC. (US) 2003-11-13 WO disclosed
US-20030119021-A1 Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions CAPROTEC BIOANALYTICS GMBH (DE) 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384800-B2 Antitumoral compounds TP53, TOP1, MCL1 FOLH1 178/4885PPARG 3291/4885PPARA 3930/4885
US-20250243174-A1 ANTITUMORAL COMPOUNDS MCL1, XPOT, GZMB FOLH1 589/4885PPARG 2167/4885PPARA 3345/4885
US-12006311-B2 Compounds for use in preventing or treating cancer UGT1A3, UGT1A1, UGT1A6 FOLH1 53/4885PPARG 458/4885PPARA 536/4885
US-20240279248-A1 SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF ADH5, ADH1A, ADH7 FOLH1 1952/4885PPARG 2580/4885PPARA 1737/4885
US-12215100-B2 Anticancer compounds TP53, MCL1, MYC FOLH1 1013/4885PPARG 2704/4885PPARA 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.